drugset / Trial / NCT04081324

A Study of Lasmiditan in Healthy Chinese Participants

NCT04081324

Phase 1 Completed 36 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a study of lasmiditan in healthy Chinese participants. The purposes are: * To evaluate the safety of lasmiditan * To learn more about how the body processes lasmiditan The study will last up to 50 days for each participant.

Timeline

Start
2019-11-13
Primary completion
2020-06-15
Completion
2020-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasmiditan Small molecule 50 mg Oral
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral

Indications

No indication recorded.